In this study, researchers are exploring a drug called **lenacapavir (LEN)** for treating **HIV-1** in children and teens who have tried other treatments. **HIV-1** is a virus that affects the immune system. LEN can be given as a pill or an injection and will be used with other medicines. The study aims to find out how safe and effective LEN is, and how well the body absorbs it.
To participate, you must weigh at least 35 kg (about 77 lbs) and have had a treatment plan that hasn't worked for over 8 weeks. You'll also need to have a certain level of the virus in your blood and limited treatment options due to resistance or other issues. There are specific health requirements to meet, like having healthy blood counts and liver function.
- Study Length: Ongoing, with regular check-ups.
- Participants receive LEN with their existing treatment plan.
- Potential risks include side effects from LEN or the combination of medicines.
How understandable was the trial content above?
Hard to understand
Easy to understand